All AbMole products are for research use only, cannot be used for human consumption.
In vitro: In bone marrow-derived macrophages (BMDMs), Sotuletinib (BLZ945) specifically inhibits CSF-1-dependent proliferation with EC50 of 67nM, and decreases CSF-1R phosphorylation. Sotuletinib (BLZ945) blocks the reciprocal effects between macrophages and glioma cells on the survival, proliferation and/ or polarization of each other to promote tumorigenesis.
In vivo: In glioma-bearing mice, BLZ945 blocks tumor progression and significantly improves survival via CSF-1R inhibition. Sotuletinib (BLZ945) also inhibits orthotopic tumor growth of patient-derived proneural tumor spheres and cell lines in vivo. Sotuletinib (BLZ945) (200 mg/kg, p.o.) decreases the growth of malignant cells in both mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis and keratin 14-expressing human papillomavirus type 16 (K14-HPV-16) transgenic model of cervical carcinogenesis.
Kidney Int. 2023 Jul;104(1):108-123.
Single cell landscape of parietal epithelial cells in healthy and diseased states
BLZ945 (Sotuletinib) purchased from AbMole
Res Sq. 2023 Jun 6;rs.3.rs-2972427.
CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity
BLZ945 (Sotuletinib) purchased from AbMole
| Molecular Weight | 398.48 |
| Formula | C20H22N4O3S |
| CAS Number | 953769-46-5 |
| Solubility (25°C) | DMSO 69 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related CSF-1R (c-Fms) Products |
|---|
| ARRY-382
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. |
| Tinengotinib
Tinengotinib is a modulator of several protein kinases, such as Aurora kinase, VEGFR kinase, and CSF-1R, etc. Tinengotinib can be used in studies related to diseases mediated by abnormalities in these kinases. |
| AMG-820
AMG-820 is an anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody. |
| CSF1R-IN-15
CSF1R-IN-15 is an inhibitor targeting CSF1R. |
| Pimicotinib
Pimicotinib is a novel, orally bioavailable, highly selective small-molecule inhibitor of colony-stimulating factor 1 (CSF-1) with antitumor activity and less inhibitory effects on c-Kit and PDGFR. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
